Pharma News

While the FDA seems to remain sceptical about the clinical benefits of Ardelyx’s chronic kidney disease (CKD) therapy Xphozah – having rejected its marketing application in 2021 – its adviso...

The FDA is considering whether some versions of the overdose reversal drug naloxone may be approvable for nonprescription use.

Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system...

CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies t...

Jnana Therapeutics and Roche have signed a second partnership and licence agreement to discover small-molecule drugs to treat cancer, immune-mediated and neurological ailments. ...

Indivior has signed a definitive agreement to acquire all outstanding shares of Opiant Pharmaceuticals for an upfront payment of $20 for each share in cash or a deal totalling nearly $145m.  ...

Walmart has agreed to become part of a nationwide opioid settlement framework to substantially resolve all opioid lawsuits and potential lawsuits by state, local, and tribal governments — if all ...

AbbVie has agreed to a $54.4 million settlement for alleged anticompetitive abuse of the generic pharmaceutical approval process involving Namenda (memantine hydrochloride), an FDA-approved drug t...

For decades, scientists have been puzzled over how exactly high blood sugar causes type 2 diabetes. 

The FDA has expanded its approval of Seagen’s Adcetris (brentuximab vedotin) in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide to treat pediatric patients t...

The FDA has asked GSK to restrict its second-line maintenance indication for its ovarian cancer drug Zejula (niraparib) to patients with deleterious or suspected deleterious germline BRCA mutation...

Satsuma Pharmaceuticals’ STS101 (dihydroergotamine nasal powder) did not pass muster in a phase 3 clinical trial for treatment of acute migraine.